Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. - Wikidata - wikimedia - TriplyDB

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

http://www.wikidata.org/entity/Q33702409

about

Mitochondrial apoptosis and BH3 mimetics Emerging therapies for acute myeloid leukemia.Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Novel investigational drugs active as single agents in multiple myeloma.What are the latest advancements in acute myeloid leukemia therapy?Biology and relevance of human acute myeloid leukemia stem cells.Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.Therapeutic inhibition of BCL-2 and related family members.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.The influential role of BCL2 family members in synovial sarcomagenesis.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.Molecular targeting in acute myeloid leukemia Emerging therapies for acute myeloid leukemia: translating biology into the clinic.Targeting apoptosis in acute myeloid leukaemia.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.Why do BCL-2 inhibitors work and where should we use them in the clinic?The BCL-2 arbiters of apoptosis and their growing role as cancer targets.T-PLL: another check on the venetoclax list?A concise review of BCL-2 inhibition in acute myeloid leukemia.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration.Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.Wild-type and mutated IDH1/2 enzymes and therapy responses.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

P2860

Q28069552-B8F259CE-CCB5-4FAD-97AE-69E3C569E9A1 Q33576363-5643F42F-AA55-42A3-AD30-F5157B1E9C32 Q38636162-E19C7DBB-EC26-458D-80FB-EF75CB3AF13C Q38637652-A288B7A7-984F-4437-925E-1F9D9B27EF58 Q38650669-E5BFBB8B-B782-4961-8F95-A97B98060AC1 Q38664735-9F51D8EB-FCD7-4CC1-8A4D-EBB8CD99ABBF Q38690290-33AC88AD-0236-4CEF-B6F9-E74BBE7DA6E9 Q38749830-234BFB31-AB40-4D27-8701-A172B0C6E84E Q38761783-DB73B152-5BB0-4917-A1A0-C09C4A8A1C19 Q38999126-719E8C65-3D75-470C-B487-200804E61C88 Q39040977-2AB85AAF-B668-4EAC-8454-BF0E0DE737E2 Q39093595-7559972A-0F25-489F-B593-B3910D8D97A7 Q39120136-C9774109-54B4-4860-B525-144A2A0A90F3 Q39137457-D952E800-5C9E-462B-BA37-D0AA37BB9B98 Q39175665-B5D33B30-0A9A-4BFB-8973-D059DDB4CBA9 Q39177442-23D0C150-F516-4FAC-B849-1D0D4298AE51 Q39267135-5091820B-039A-4FF6-B8BD-23881D0F190F Q40066050-95FA02F5-87BB-4E74-9A25-2432D411CE17 Q40537266-55F54598-20A6-4947-BC4B-CE3221CF2279 Q40597634-16F2F2E1-5621-43D9-9E21-1D1E8ADEE430 Q41558732-2B4A04EC-6C80-4CC0-948C-C55C8A1803EB Q41984963-F8126DC6-6389-45CE-B49F-A2A29248C7E0 Q44489428-7CE94DC4-BAFB-4B07-9C5D-811CC3ECB4F4 Q45057327-81F08B36-1294-4453-8FDE-FF2DA0687285 Q45120868-1817CE32-5F3A-490F-8D83-D76EE89A7956 Q46370948-25D18418-4828-4326-B280-A812A4811402 Q46633482-B4805A6B-CAB7-4680-A679-EFB388DA8F3D Q46932352-E59CB77B-B46F-4B83-8193-DE7729E64039 Q47146837-93EED212-4205-4CC8-BE74-9226392A5D61 Q47159040-5D682C0A-C683-46F1-922E-2689A9A46673 Q47166330-8ABAD2D9-B7B2-485E-BF42-AE8C22F7B105 Q47235165-2B110DD4-3898-4C28-9CDC-C22A8DFA4E4E Q47271349-A67074CD-B728-4309-9351-082B10F0AC94 Q47339574-3E0ECACB-5263-4849-A48B-613812D34D10 Q47610956-F81490A1-5F36-4EF9-B80C-553B76882EEF Q47661789-1100727D-E5A1-40E8-8649-7EA200508CDD Q47670493-4EBA1BC8-3717-4C58-94E5-CDE614148DC9 Q47713415-8A16B8F7-FEEC-454D-BCBE-90C4230A243E Q47741553-BC05E76D-F710-4D5A-A72E-B5AFAE2B66FA Q47965108-FA5ED96B-6B55-46EE-9379-691838A1E56F

P2860

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

http://www.wikidata.org/entity/Q33702409

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@ast

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@en

type

label

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@ast

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@en

prefLabel

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@ast

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@en

P1433

Q33702409-902E1A0D-C1A7-45CF-AF6B-D7135C9039FA

P1476

Q33702409-7C128B20-634A-4C89-9156-30958327DF68

P2093

Q33702409-0FCFED1D-B413-45EE-ADAF-934F7505CDCA

Q33702409-1E430D51-7189-4F93-AE54-D88011F4C51E

Q33702409-2E214C76-C853-4B31-B4CE-3C1646ECD20B

Q33702409-4C9E2785-C28F-4B64-BC56-8149B0541491

Q33702409-56DB9620-E19F-40D3-97D7-14CF1956BDDB

Q33702409-5B7D79B0-29EB-47B6-BD77-7C6ABA15F1D1

Q33702409-66061E82-4B9A-4395-8DB9-9BEDC7A9E054

Q33702409-6DDE85ED-6BC3-4419-B12C-17D47DDC4B23

Q33702409-77090CEC-2F52-4E22-B63C-D1BC0151996D

Q33702409-87F9645C-D6D1-4554-B4DB-D2EE49F5A8E9

P2860

Q33702409-01061B7F-8F57-46A1-A6EE-BD74CFA3F790

Q33702409-05FA5366-E681-41EB-B1AB-D455521124F3

Q33702409-07A112EB-3F58-4F53-96A0-AA5C6BB5F655

Q33702409-10A35ADA-20BA-4FB6-8685-C91EFB908098

Q33702409-1E208935-DA82-4A8D-98E4-8DA1799FD0A2

Q33702409-2E1D0667-9C37-4B4F-9CD8-AE2154DDDF35

Q33702409-2FA504B1-A550-4F56-A3B0-33362D5028CD

Q33702409-324A6B87-4ACC-42A0-BE9E-672F6F157108

Q33702409-36319406-4EF5-474A-9DEE-1A45E8EC4DCF

Q33702409-391C2EA3-1392-40D5-BF0F-4508DFF21D31

P304

Q33702409-FD9BBEDD-9C92-43C6-9B21-8B50D38BCCE9

P31

Q33702409-7E04AC82-DED7-42B0-97A4-55EB887A35E9

P356

Q33702409-29FFD9F7-C749-4899-BDC5-1F95C01D5BB2

P433

Q33702409-7828C666-BA69-48EE-9644-CA0AE5D69AF0

P478

Q33702409-4F26F625-E70A-457A-AC63-D4F244881833

P50

Q33702409-4F2ED273-30DD-41E9-912A-5CA9C13274F2

Q33702409-9048F6F3-5203-4A8D-8D17-932BA3090F53

Q33702409-A603F33D-CCA3-4E75-8F17-87FB09F8E008

P577

Q33702409-A2A45AF8-B807-47E4-A7ED-91462EC868ED

P698

Q33702409-D6871194-1BBE-459E-BE0E-D41E138D5758

P921

Q33702409-81516025-BE2C-4E93-AB56-7CC1A3049CBC

P932

Q33702409-CDF68252-E926-40EB-B956-318D6ABBBF28

P356

2159-8290.CD-16-0313

P1433

Cancer Discovery

P1476

Efficacy and Biological Correl ...... th Acute Myelogenous Leukemia.

@en

P2093

Ahmed Hamed Salem

http://www.w3.org/2001/XMLSchema#string

Anthony Letai

http://www.w3.org/2001/XMLSchema#string

Brenda Chyla

http://www.w3.org/2001/XMLSchema#string

Courtney D DiNardo

http://www.w3.org/2001/XMLSchema#string

Daniel A Pollyea

http://www.w3.org/2001/XMLSchema#string

Evelyn McKeegan

http://www.w3.org/2001/XMLSchema#string

Jalaja Potluri

http://www.w3.org/2001/XMLSchema#string

Joel Leverson

http://www.w3.org/2001/XMLSchema#string

Justin L Ricker

http://www.w3.org/2001/XMLSchema#string

Leah Hogdal

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

The Bcl-2 apoptotic switch in cancer development and therapy

Recurring mutations found by sequencing an acute myeloid leukemia genome

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

P304

1106-1117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-16-0313

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Marina Konopleva

P577

2016-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27520294

http://www.w3.org/2001/XMLSchema#string

P921

P932

5436271

http://www.w3.org/2001/XMLSchema#string